Results of the first randomised trial testing the criteria used to diagnose heart attack are presented today in a Hot Line Session at ESC Congress 2018 and published in The Lancet.
Aug 28, 2018
0
0
The optimal timing of invasive evaluation after a heart attack has been examined in a randomised trial. The late breaking results from the VERDICT trial are presented today in a Hot Line Session at ESC Congress 2018.
Aug 28, 2018
0
0
The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart failure, sinus rhythm, and ...
Aug 27, 2018
0
0
Long-term antiplatelet monotherapy after stenting is safe but does not reduce the risk of death or heart attack compared to standard dual antiplatelet therapy, according to late breaking results from the GLOBAL LEADERS trial ...
Aug 27, 2018
0
3
The initial findings of a study on spontaneous coronary artery dissection, a major cause of heart attacks in women, are reported today in a late breaking science session at ESC Congress 2018.
Aug 25, 2018
0
650
(HealthDay)—For patients with depression following recent acute coronary syndrome (ACS), escitalopram results in lower risk of major adverse cardiac events (MACE) versus placebo, according to a study published in the July ...
Jul 25, 2018
0
1
Published in today's Medical Journal of Australia, the study of 2898 patients (2183 men, 715 women) reveals that six months after hospital discharge, death rates and serious adverse cardiovascular events in women presenting ...
Jul 22, 2018
0
7
(HealthDay)—For patients who experienced a transient ischemic attack (TIA) or minor stroke, the rate of a composite of stroke, acute coronary syndrome, or death from cardiovascular causes is 12.9 percent at five years, ...
Jun 28, 2018
0
0
Pilot data from a recent study suggest that patients with short sleep have over two times the odds of readmission than those with sufficient sleep duration during the month following acute coronary syndrome evaluation.
Jun 4, 2018
0
1
(HealthDay)—Elevated fibroblast growth factor 23 (FGF-23) is associated with increased risk of recurrent major cardiovascular (CV) events in patients after an acute coronary syndrome (ACS), according to a study published ...
Apr 23, 2018
0
6
